FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950777189> ?p ?o ?g. }

• W2950777189 endingPage "1322" @default.
• W2950777189 startingPage "1322" @default.
• W2950777189 abstract "Background: Ph-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL in both children and adults (Roberts, NEJM 2014, JCO 2017; Jain, Blood 2017). Ph-like ALL is characterized by a multitude of genetic aberrations, leading to activation of the JAK-STAT signaling pathway or the ABL kinase pathway, which may be amenable to targeted therapies. Methods: We designed an investigator-initiated phase I/II trial using ruxolitinib (JAK inhibitor) or dasatinib (ABL1 kinase inhibitor), in combination with chemotherapy for patients (pts) with relapsed/refractory (R/R) Ph-like ALL aged ≥10 years (yrs) old (NCT02420717). Pts with BCR-ABL1 fusion were excluded. Pts with R/R B-ALL were screened for genomic aberrations seen in Ph-like ALL. Testing methods included flow cytometry for CRLF2 ; NGS panel, covering all exons of JAK2 ; FISH panel (CRLF2, ABL1, ABL2, CSF1R, JAK2, EPOR, PDGFRB); Ph-like ALL fusion panel (Child Lab, Columbus, OH). Once the genomic aberration was identified, pts were either enrolled on ruxolitinib arm (CRLF2 overexpression, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation), or dasatinib arm (ABL1, ABL2, PDGFRB fusions) (Figure 1). The primary objective (Phase I) is to determine the safety and MTD of ruxolitinib in combination with chemotherapy. The secondary objectives include efficacy. Three dose levels of ruxolitinib are planned (level 1: 15mg BID, level 2: 20mg BID, level 3: 25mg BID). The dose of dasatinib is 100mg once daily. Ruxolitinib (or dasatinib) was initiated on cycle 1 day 1 and continued daily. Hyper-CVAD chemotherapy was added after cycle 1, or earlier if evidence of disease progression. Phase II will commence after the MTD is established. We report here interim results of the phase I part of the trial. Results: 9pts have been treated. Median age 24 yrs (range 18-62). Median no. of prior therapies 3 (2-10). 3 pts had a prior allo-SCT, and 1 pt had failed CD19 CART. 8 pts were treated on the ruxolitinib arm (15mg BID, n=5; 20mg BID, n=3), and 1 pt on the dasatinib arm. Genomic aberrations in the ruxolitinib arm included 7 pts with CRLF2 overexpression by flow-cytometry (confirmed by CRLF2 FISH), and 1 pt with a novel JAK2 fusion (HMBOX1-JAK2). 3 of the 7 pts with CRLF2 rearrangement had a JAK2 mutation (R683S, T875N, I682F). Dose levels 1 and 2 have been completed without any DLT; the trial is now enrolling at dose level 3. Two pt in dose level 1 did not receive chemotherapy, and the cohort was expanded to 5 pts to allow for DLT assessment. One pt with CRLF2+/JAK2 R683S treated at the dose level 2 achieved a CRp. One pt with CRLF2+/JAK2 I682F (dose level 1) had a transient reduction in peripheral blood (PB) blasts during the ruxolitinib monotherapy. The sole pt on the dasatinib arm had NUP214-ABL1 fusion. This pt had reduction in PB blasts with dasatinib, but did not respond in the bone marrow (BM). CyTOF analysis was performed on pretreatment and post-TKI (Day 21) BM or PB samples in 5 pts (4 pts ruxolitinib arm; 1 pt dasatinib arm). TKI therapy reduced pTyr by >70% in CD10+/CD19+ ALL cells in 3 of the 4 pts, and to a lesser degree the downstream p4EBP1 in 4 pts (33-91% inhibition). One pt with wtJAK2/CRLF2+ had no modulation of pTyr, pStat3 or pp38; another pt with same genotype had no change in pStat3 or pp38 despite decrease in pTyr, and both pts progressed during ruxolitinib therapy. In two pts with most significant reduction in pTyr there was concomitant reduction in pStat3 in CRLF2+ ALL and of pp38 and p4EBP1, and corresponding decrease in BM blasts (NUP214-ABL1 rearranged ALL, 58%→8%; and JAK2 T875N CRLF2+ ALL, 90%→58%, Figure 2). Notably, expression of anti-apoptotic protein BCL-2 remained unchanged or was induced in residual ALL cells in all except one pt. Conclusions: The combination of ruxolitinib and chemotherapy is safe, with no DLT seen with combinations of ruxolitinib at two initial dose levels or dasatinib with hyper-CVAD. Preliminary clinical activity in R/R heavily pre-treated ALL pts is limited at the dose levels studied. CyTOF analyses showed lack of modulation of signaling in pts with wtJAK2/CRLF2 accompanied by ALL progression; partial down regulation of JAK-STAT signaling in mutJAK2/CRLF2+ by ruxolitinib and in ABL1-rearranged ALL by dasatinib, associated with decrease in % BM blasts. Notably, we observed compensatory induction of anti-apoptotic BCL-2 protein, potentially conferring resistance to TKIs. The study continues to enroll at a higher dose of ruxolitinib. Disclosures Jain: Novartis: Honoraria, Membership on an entity9s Board of Directors or advisory committees; Genentech: Research Funding; Servier: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Incyte: Research Funding; Pharmacyclics: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; ADC Therapeutics: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Verastem: Research Funding; Pfizer: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Novimmune: Honoraria, Membership on an entity9s Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity9s Board of Directors or advisory committees; BMS: Research Funding. Jabbour: Bristol-Myers Squibb: Consultancy. McKay: 6 ImmunoGen, Inc.Waltham, MA: Employment. Takahashi: Symbio Pharmaceuticals: Consultancy. Wierda: Acerta: Research Funding; Genzyme: Consultancy, Honoraria; The University of Texas MD Anderson Cancer Center: Employment; Merck: Consultancy, Honoraria; Genentech/Roche: Consultancy, Honoraria, Research Funding; Emergent: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Janssen: Research Funding; Celgene: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Research Funding; GSK/Novartis: Consultancy, Honoraria, Research Funding; Karyopharm: Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Juno: Research Funding; Kite: Research Funding. Verstovsek: Blueprint Medicines Corp: Research Funding; Pfizer: Research Funding; Galena BioPharma: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding; Celgene: Research Funding; Gilead: Research Funding; Gilead: Research Funding; Bristol Myers Squibb: Research Funding; Lilly Oncology: Research Funding; Bristol Myers Squibb: Research Funding; Incyte: Research Funding; Roche: Research Funding; Galena BioPharma: Research Funding; Seattle Genetics: Research Funding; Genentech: Research Funding; CTI BioPharma Corp: Research Funding; Promedior: Research Funding; Seattle Genetics: Research Funding; Genentech: Research Funding; CTI BioPharma Corp: Research Funding; Astrazeneca: Research Funding; Incyte: Research Funding; Celgene: Research Funding; Blueprint Medicines Corp: Research Funding; Pfizer: Research Funding; Lilly Oncology: Research Funding; Roche: Research Funding; NS Pharma: Research Funding; Astrazeneca: Research Funding. O9Brien: Alexion: Consultancy; Celgene: Consultancy; Janssen: Consultancy; ProNAI: Other: Research Support: Honorarium, Research Funding; GSK: Consultancy; Pharmacyclics: Consultancy, Other: Research Support: Honorarium, Research Funding; Vaniam Group LLC: Consultancy; Astellas: Consultancy; Aptose Biosciences, Inc.: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy, Other: Research Support: Honorarium, Research Funding; Gilead Sciences, Inc.: Consultancy, Other: Research Support: Honorarium, Research Funding; Regeneron: Other: Research Support: Honorarium, Research Funding; CLL Global Research Foundation: Membership on an entity9s Board of Directors or advisory committees; Acerta: Other: Research Support: Honorarium, Research Funding; Amgen: Consultancy; AbbVie: Consultancy; Sunesis: Consultancy. Cortes: Sun Pharma: Research Funding; Novartis Pharmaceuticals Corporation: Consultancy, Research Funding; ARIAD: Consultancy, Research Funding; Teva: Research Funding; BMS: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding. Mullighan: Loxo Oncology: Research Funding; Amgen: Consultancy. Kantarjian: Pfizer: Research Funding; Novartis: Research Funding; Amgen: Research Funding; Bristol-Meyers Squibb: Research Funding; Delta-Fly Pharma: Research Funding; ARIAD: Research Funding." @default.
• W2950777189 created "2019-06-27" @default.
• W2950777189 creator A5000750846 @default.
• W2950777189 creator A5005660335 @default.
• W2950777189 creator A5006104041 @default.
• W2950777189 creator A5010663972 @default.
• W2950777189 creator A5015101485 @default.
• W2950777189 creator A5019724584 @default.
• W2950777189 creator A5020340537 @default.
• W2950777189 creator A5021380291 @default.
• W2950777189 creator A5022647201 @default.
• W2950777189 creator A5024081198 @default.
• W2950777189 creator A5028591457 @default.
• W2950777189 creator A5043585566 @default.
• W2950777189 creator A5043947276 @default.
• W2950777189 creator A5046212168 @default.
• W2950777189 creator A5047351832 @default.
• W2950777189 creator A5048744038 @default.
• W2950777189 creator A5049385583 @default.
• W2950777189 creator A5051949215 @default.
• W2950777189 creator A5055404021 @default.
• W2950777189 creator A5060818696 @default.
• W2950777189 creator A5061026876 @default.
• W2950777189 creator A5062979200 @default.
• W2950777189 creator A5071658726 @default.
• W2950777189 creator A5085521139 @default.
• W2950777189 creator A5089295627 @default.
• W2950777189 creator A5089428686 @default.
• W2950777189 creator A5090435894 @default.
• W2950777189 creator A5090618436 @default.
• W2950777189 date "2017-12-07" @default.
• W2950777189 modified "2023-10-18" @default.
• W2950777189 title "Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial" @default.
• W2950777189 doi "https://doi.org/10.1182/blood.v130.suppl_1.1322.1322" @default.
• W2950777189 hasPublicationYear "2017" @default.
• W2950777189 type Work @default.
• W2950777189 sameAs 2950777189 @default.
• W2950777189 citedByCount "3" @default.
• W2950777189 countsByYear W29507771892018 @default.
• W2950777189 countsByYear W29507771892021 @default.
• W2950777189 countsByYear W29507771892023 @default.
• W2950777189 crossrefType "journal-article" @default.
• W2950777189 hasAuthorship W2950777189A5000750846 @default.
• W2950777189 hasAuthorship W2950777189A5005660335 @default.
• W2950777189 hasAuthorship W2950777189A5006104041 @default.
• W2950777189 hasAuthorship W2950777189A5010663972 @default.
• W2950777189 hasAuthorship W2950777189A5015101485 @default.
• W2950777189 hasAuthorship W2950777189A5019724584 @default.
• W2950777189 hasAuthorship W2950777189A5020340537 @default.
• W2950777189 hasAuthorship W2950777189A5021380291 @default.
• W2950777189 hasAuthorship W2950777189A5022647201 @default.
• W2950777189 hasAuthorship W2950777189A5024081198 @default.
• W2950777189 hasAuthorship W2950777189A5028591457 @default.
• W2950777189 hasAuthorship W2950777189A5043585566 @default.
• W2950777189 hasAuthorship W2950777189A5043947276 @default.
• W2950777189 hasAuthorship W2950777189A5046212168 @default.
• W2950777189 hasAuthorship W2950777189A5047351832 @default.
• W2950777189 hasAuthorship W2950777189A5048744038 @default.
• W2950777189 hasAuthorship W2950777189A5049385583 @default.
• W2950777189 hasAuthorship W2950777189A5051949215 @default.
• W2950777189 hasAuthorship W2950777189A5055404021 @default.
• W2950777189 hasAuthorship W2950777189A5060818696 @default.
• W2950777189 hasAuthorship W2950777189A5061026876 @default.
• W2950777189 hasAuthorship W2950777189A5062979200 @default.
• W2950777189 hasAuthorship W2950777189A5071658726 @default.
• W2950777189 hasAuthorship W2950777189A5085521139 @default.
• W2950777189 hasAuthorship W2950777189A5089295627 @default.
• W2950777189 hasAuthorship W2950777189A5089428686 @default.
• W2950777189 hasAuthorship W2950777189A5090435894 @default.
• W2950777189 hasAuthorship W2950777189A5090618436 @default.
• W2950777189 hasConcept C121332964 @default.
• W2950777189 hasConcept C126322002 @default.
• W2950777189 hasConcept C142424586 @default.
• W2950777189 hasConcept C143998085 @default.
• W2950777189 hasConcept C2776112149 @default.
• W2950777189 hasConcept C2776694085 @default.
• W2950777189 hasConcept C2777583451 @default.
• W2950777189 hasConcept C2778336483 @default.
• W2950777189 hasConcept C2778461978 @default.
• W2950777189 hasConcept C2778729363 @default.
• W2950777189 hasConcept C2779536868 @default.
• W2950777189 hasConcept C2780007613 @default.
• W2950777189 hasConcept C2780076729 @default.
• W2950777189 hasConcept C2781107101 @default.
• W2950777189 hasConcept C2909962599 @default.
• W2950777189 hasConcept C31760486 @default.
• W2950777189 hasConcept C71924100 @default.
• W2950777189 hasConcept C87355193 @default.
• W2950777189 hasConceptScore W2950777189C121332964 @default.
• W2950777189 hasConceptScore W2950777189C126322002 @default.
• W2950777189 hasConceptScore W2950777189C142424586 @default.
• W2950777189 hasConceptScore W2950777189C143998085 @default.
• W2950777189 hasConceptScore W2950777189C2776112149 @default.
• W2950777189 hasConceptScore W2950777189C2776694085 @default.
• W2950777189 hasConceptScore W2950777189C2777583451 @default.
• W2950777189 hasConceptScore W2950777189C2778336483 @default.
• W2950777189 hasConceptScore W2950777189C2778461978 @default.
• W2950777189 hasConceptScore W2950777189C2778729363 @default.

• next